Amit Kakkar, MD
Interventional Cardiology · East Chicago, INNPI 1144489048
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,571 of the $19,818 with a category attached, or 88.7%. It is spread thinly across 53 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.
Across 466 payments — averaging $42.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$3K
- Penumbra, Inc.$3K
- Novartis$1K
- Abbott$936
- Johnson & Johnson$804
- Biotronik Inc.$708
- plus $10K from 47 others
What the payments were for
- Consulting fees$2501%
- Travel & lodging$1,90310%
- Food & beverage$17,57189%
- Education$340%
- Entertainment$600%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$2,667
- Peripheral Orbital Atherectomy System$1,092
- Diamondback Peripheral$747
- Diamondback Coronary$500
- Rapiblyk$485
- Alto Abdominal Stent Graft System$460
- Coronary Orbital Atherectomy System$450
- Rotarex$415
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$300
- CVI SYSTEMS$294
- Indigo System$283
- Ruby$278
- XARELTO$277
- LEQVIO$261
- Orsiro Mission$258
- BioMonitor$234
- Edora 8 DR-T$234
- Solia$234
- Rivacor 7 DR-T$234
- Acticor 7 VR-T DX$234
How this compares
$19,818 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 111 | $95,212 |
| EliquisApixaban | 74 | $55,422 |
| FarxigaDapagliflozin Propanediol | 41 | $37,441 |
| XareltoRivaroxaban | 31 | $25,500 |
| JardianceEmpagliflozin | 27 | $18,884 |
| BrilintaTicagrelor | 31 | $17,180 |
| Repatha PushtronexEvolocumab | 15 | $12,575 |
| DapagliflozinDapagliflozin Propanediol | 13 | $6,870 |
| Ranolazine ErRanolazine | 12 | $4,879 |
| ClopidogrelClopidogrel Bisulfate | 125 | $1,177 |
| Metoprolol Succinate | 175 | $921 |
| Atorvastatin Calcium | 177 | $852 |
| Amlodipine Besylate | 159 | $711 |
| Rosuvastatin Calcium | 70 | $667 |
| Cilostazol | 44 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,306 | $95,212111 claims |
| PfizerEliquis | $321 | $55,42274 claims |
| AstraZenecaFarxiga, Brilinta | $663 | $54,62172 claims |
| Johnson & JohnsonXarelto | $804 | $25,50031 claims |
| Boehringer IngelheimJardiance | $269 | $18,88427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in East Chicago
- Samer AbbasEast Chicago$395K
- Dean FerreraEast Chicago$180K
- Arif KhalilEast Chicago$15K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.